January 21, 2009European Journal of Heart Failure192 citationsOpen Access
View Full PaperLevosimendan vs. Dobutamine: Outcomes for Acute Heart Failure Patients on β-Blockers in SURVIVE
Structured PICO
Does levosimendan improve outcomes compared to dobutamine in patients hospitalized with acute decompensated heart failure on beta-blocker therapy?
P
Population
Patients hospitalized with acute decompensations of heart failure, specifically those with a history of CHF or on beta-blocker therapy
I
Intervention
Levosimendan
C
Comparator
Dobutamine
Preliminary findings suggest levosimendan may offer benefits over dobutamine in acute heart failure patients, particularly those with a history of CHF or concurrent beta-blocker use.
Abstract
Levosimendan may be better than dobutamine for treating patients with a history of CHF or those on beta-blocker therapy when they are hospitalized with acute decompensations. These findings are preliminary but important for planning future studies.